Clinical utility of Aspergillus galactomannan and PCR in bronchoalveolar lavage fluid for the diagnosis of invasive pulmonary aspergillosis in patients with haematological malignancies

Diagnostic Microbiology and Infectious Disease

Volumn 79, Issue 3, 2014, Pages 322-327

  Heng, Siow Chin ^a   Chen, Sharon C A ^b   Morrissey, C Orla ^a,c   Thursky, Karin ^d,e   Manser, Renee L ^d   De Silva, Harini D ^c   Halliday, Catriona L ^b   Seymour, John F ^d,e   Nation, Roger L ^a   Kong, David C M ^a   Slavin, Monica A ^d,e  

^a MONASH UNIVERSITY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c BURNET INSTITUTE   (Australia)

^d PETER MACCALLUM CANCER CENTRE   (Australia)

^e UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aspergillus PCR; Diagnosis; Galactomannan; Haematology

Indexed keywords

ANTIFUNGAL AGENT; BETA LACTAM; GALACTOMANNAN; FUNGAL DNA; FUNGUS ANTIGEN; MANNAN;

ADULT; AGED; ARTICLE; ASPERGILLUS; BLOOD SAMPLING; BRONCHOSCOPY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; INTERMETHOD COMPARISON; LUNG ASPERGILLOSIS; LUNG INFILTRATE; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; STANDARD; ADOLESCENT; CHEMISTRY; CLINICAL TRIAL; COMPARATIVE STUDY; COMPLICATION; EVALUATION STUDY; GENETICS; HEMATOLOGIC DISEASE; IMMUNOASSAY; IMMUNOLOGY; INVASIVE PULMONARY ASPERGILLOSIS; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, FUNGAL; ASPERGILLUS; BRONCHOALVEOLAR LAVAGE FLUID; DNA, FUNGAL; HEMATOLOGIC NEOPLASMS; HUMANS; IMMUNOASSAY; INVASIVE PULMONARY ASPERGILLOSIS; MALE; MANNANS; MIDDLE AGED; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84902120398     PISSN: 07328893     EISSN: 18790070     Source Type: Journal    
DOI: 10.1016/j.diagmicrobio.2014.03.020     Document Type: Article

References (37)

1. Ananda-Rajah M.R., Grigg A., Downey M.T., Bajel A., Spelman T., Cheng A., et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica 2012, 97:459-463.
2. Becker M.J., Lugtenburg E.J., Cornelissen J.J., Van Der Schee C., Hoogsteden H.C., De Marie S. Galactomannan detection in computerized tomography-based broncho-alveolar lavage fluid and serum in haematological patients at risk for invasive pulmonary aspergillosis. Br J Haematol 2003, 121:448-457.
3. Bergeron A., Belle A., Sulahian A., Lacroix C., Chevret S., Raffoux E., et al. Contribution of galactomannan antigen detection in BAL to the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies. Chest 2010, 137:410-415.
4. Cuenca Estrella M., Bassetti M., Lass-Florl C., Racil Z., Richardson M., Rogers T.R. Detection and investigation of invasive mould disease. J Antimicrob Chemother 2011, 66:i15-i24.
5. De Pauw B., Walsh T.J., Donnelly J.P., Stevens D.A., Edwards J.E., Calandra T., et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008, 46:1813-1821.
6. D'Haese J., Theunissen K., Vermeulen E., Schoemans H., De Vlieger G., Lammertijn L., et al. Detection of galactomannan in bronchoalveolar lavage fluid samples of patients at risk for invasive pulmonary aspergillosis: analytical and clinical validity. J Clin Microbiol 2012, 50:1258-1263.
7. Donnelly J.P. Defining invasive aspergillosis: what the revised EORTC/MSG definitions have in store. Aspergillosis: from diagnosis to prevention 2010, 423-435. Springer, New York. A.C. Pasqualotto (Ed.).
8. Frealle E., Decrucq K., Botterel F., Bouchindhomme B., Camus D., Dei-Cas E., et al. Diagnosis of invasive aspergillosis using bronchoalveolar lavage in haematology patients: influence of bronchoalveolar lavage human DNA content on real-time PCR performance. Eur J Clin Microbiol Infect Dis 2009, 28:223-232.
9. Guy S.D., Tramontana A.R., Worth L.J., Lau E., Hicks R.J., Seymour J.F., et al. Use of FDG PET/CT for investigation of febrile neutropenia: evaluation in high-risk cancer patients. Eur J Nucl Med Mol Imaging 2012, 39:1348-1355.
10. Halliday C., Wu Q.X., James G., Sorrell T. Development of a nested qualitative real-time PCR assay to detect Aspergillus species DNA in clinical specimens. J Clin Microbiol 2005, 43:5366-5368.
11. Heng S.C., Morrissey C.O., Chen S.C.-A., Thursky K., Manser R.L., Nation R.L., et al. Utility of bronchoalveolar lavage fluid galactomannan alone or in combination with PCR for the diagnosis of invasive aspergillosis in adult hematology patients: a systematic review and meta-analysis. Crit Rev Microbiol 2013, Jun 25. [Epub ahead of print] PubMed PMID: 23799871.
12. Herbrecht R., Letscher-Bru V., Oprea C., Lioure B., Waller J., Campos F., et al. Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002, 20:1898-1906.
13. Hope W.W., Kruhlak M.J., Lyman C.A., Petraitiene R., Petraitis V., Francesconi A., et al. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J Infect Dis 2007, 195:455-466.
14. Hsu L.Y., Ding Y., Phua J., Koh L.P., Chan D.S., Khoo K.L., et al. Galactomannan testing of bronchoalveolar lavage fluid is useful for diagnosis of invasive pulmonary aspergillosis in hematology patients. BMC Infect Dis 2010, 10:44.
15. Khot P.D., Ko D.L., Hackman R.C., Fredricks D.N. Development and optimization of quantitative PCR for the diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. BMC Infect Dis 2008, 8:73.
16. Kontoyiannis D.P., Marr K.A., Park B.J., Alexander B.D., Anaissie E.J., Walsh T.J., et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010, 50:1091-1100.
17. Luong M.L., Filion C., Labbe A.C., Roy J., Pepin J., Cadrin-Tourigny J., et al. Clinical utility and prognostic value of bronchoalveolar lavage galactomannan in patients with hematologic malignancies. Diagn Microbiol Infect Dis 2010, 68:132-139.
18. Maertens J., Maertens V., Theunissen K., Meersseman W., Meersseman P., Meers S., et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009, 49:1688-1693.
19. Maschmeyer G., Beinert T., Buchheidt D., Cornely O.A., Einsele H., Heinz W., et al. Diagnosis and antimicrobial therapy of lung infiltrates in febrile neutropenic patients: Guidelines of the infectious diseases working party of the German Society of Haematology and Oncology. Eur J Cancer 2009, 45:2462-2472.
20. Mennink-Kersten M.A., Donnelly J.P., Verweij P.E. Detection of circulating galactomannan for the diagnosis and management of invasive aspergillosis. Lancet Infect Dis 2004, 4:349-357.
21. Mikulska M., Furfaro E., Del Bono V., Raiola A.M., Ratto S., Bacigalupo A., et al. Piperacillin/tazobactam (Tazocin) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother 2012, 67:1746-1748.
22. Morrissey C.O., Chen S.C., Sorrell T.C., Bradstock K.F., Szer J., Halliday C.L., et al. Design issues in a randomized controlled trial of a pre-emptive versus empiric antifungal strategy for invasive aspergillosis in patients with high-risk hematologic malignancies. Leuk Lymphoma 2011, 52:179-193.
23. Morrissey C.O., Chen S.C., Sorrell T.C., Milliken S., Bardy P.G., Bradstock K.F., et al. Galactomannan and PCR versus culture and histology for directing use of antifungal treatment for invasive aspergillosis in high-risk haematology patients: a randomised controlled trial. Lancet Infect Dis 2013, 13:519-528.
24. Musher B., Fredricks D., Leisenring W., Balajee S.A., Smith C., Marr K.A. Aspergillus galactomannan enzyme immunoassay and quantitative PCR for diagnosis of invasive aspergillosis with bronchoalveolar lavage fluid. J Clin Microbiol 2004, 42:5517-5522.
25. Nguyen M.H., Leather H., Clancy C.J., Cline C., Jantz M.A., Kulkarni V., et al. Galactomannan testing in bronchoalveolar lavage fluid facilitates the diagnosis of invasive pulmonary aspergillosis in patients with hematologic malignancies and stem cell transplant recipients. Biol Blood Marrow Transplant 2011, 17:1043-1050.
26. Park S.Y., Lee S.O., Choi S.H., Sung H., Kim M.N., Choi C.M., et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect 2010, 61:492-498.
27. Penack O., Rempf P., Graf B., Blau I.W., Thiel E. Aspergillus galactomannan testing in patients with long-term neutropenia: implications for clinical management. Ann Oncol 2008, 19:984-989.
28. Racil Z., Kocmanova I., Toskova M., Buresova L., Weinbergerova B., Lengerova M., et al. Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance. Int J Infect Dis 2011, 15:e874-e881.
29. Rano A., Agusti C., Jimenez P., Angrill J., Benito N., Danes C., et al. Pulmonary infiltrates in non-HIV immunocompromised patients: a diagnostic approach using non-invasive and bronchoscopic procedures. Thorax 2001, 56:379-387.
30. Reinwald M., Hummel M., Kovalevskaya E., Spiess B., Heinz W.J., Vehreschild J.J., et al. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother 2012, 67:2260-2267.
31. Reinwald M., Spiess B., Heinz W.J., Vehreschild J.J., Lass-Florl C., Kiehl M., et al. Diagnosing pulmonary aspergillosis in patients with hematological malignancies: a multicenter prospective evaluation of an Aspergillus PCR assay and a galactomannan ELISA in bronchoalveolar lavage samples. Eur J Haematol 2012, 89:120-127.
32. Sanguinetti M., Posteraro B., Pagano L., Pagliari G., Fianchi L., Mele L., et al. Comparison of real-time PCR, conventional PCR, and galactomannan antigen detection by enzyme-linked immunosorbent assay using bronchoalveolar lavage fluid samples from hematology patients for diagnosis of invasive pulmonary aspergillosis. J Clin Microbiol 2003, 41:3922-3925.
33. Steinbach W.J., Marr K.A., Anaissie E.J., Azie N., Quan S.P., Meier-Kriesche H.U., et al. Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 2012, 65:453-464.
34. Tam C.S., O'Reilly M., Andresen D., Lingaratnam S., Kelly A., Burbury K., et al. Use of empiric antimicrobial therapy in neutropenic fever. Australian Consensus Guidelines 2011 Steering Committee. Intern Med J 2011, 41:90-101.
35. Tuon F.F. A systematic literature review on the diagnosis of invasive aspergillosis using polymerase chain reaction (PCR) from bronchoalveolar lavage clinical samples. Rev Iberoam Micol 2007, 24:89-94.
36. von Eiff M., Roos N., Schulten R., Hesse M., Zuhlsdorf M., van de Loo J. Pulmonary aspergillosis: early diagnosis improves survival. Respiration 1995, 62:341-347.
37. White P.L., Bretagne S., Klingspor L., Melchers W.J., McCulloch E., Schulz B., et al. Aspergillus PCR: one step closer to standardization. J Clin Microbiol 2010, 48:1231-1240.